iPierian is a South San Francisco-based biopharmaceutical company focused on the industrialization of induced pluripotent stem cell (iPS) technology with the mission of creating new therapeutics through cellular reprogramming and directed differentiation of patient cells. The initial focus of the company is in neurodegeneration, particularly spinal muscular atrophy (SMA), amyotrophic lateral sclerosis (ALS) and Parkinson’s disease as well as in cardiovascular disease, where iPierian has a collaboration with The Gladstone Institute of Cardiovascular Disease and Dr. Deepak Srivastava, the institute’s director. iPierian plans to enhance its partnership efforts to further expand into metabolic diseases.
iPierian, Inc. is backed by a group of top-tier investors including Kleiner Perkins Caufield & Byers, Highland Capital Partners, MPM Capital and FinTech Global Capital.
For more information on iPierian, Inc., please visit their web site at www.ipierian.com.
iPierian, Inc. is backed by a group of top-tier investors including Kleiner Perkins Caufield & Byers, Highland Capital Partners, MPM Capital and FinTech Global Capital.
For more information on iPierian, Inc., please visit their web site at www.ipierian.com.
Total raised: $52M
Investors 1
| Date | Name | Website |
| - | ATEL Capit... | atel.com |
Funding Rounds 2
| Date | Series | Amount | Investors |
| 04.09.2013 | - | $30M | - |
| 08.07.2010 | Series B | $22M | - |
Mentions in press and media 11
| Date | Title | Description |
| 18.10.2013 | Health IT deals help push software deals to 12-year high but life science struggles | Here were the biggest health IT deals for the quarter based on data from the MoneyTree Report and Mercom Capital Group’s Healthcare IT report. Evolent Health raised $100 million. EHR provider Practice Fusion raised $70 million. MedSynergies... |
| 04.09.2013 | UPDATED: Pursuing Alzheimer's, iPierian grabs $30M and spins off orphan drug biotech | iPierian CEO Nancy Stagliano After taking the helm and pointing South San Francisco-based iPierian in a new direction, CEO Nancy Stagliano today unveiled a $30 million venture round designed to get her crew into the clinic with a lead antib... |
| 04.09.2013 | Neuro drug developer iPierian nets $30M, spins off new company for rare disease R&D program | MPM Capital co-led the round along with GlaxoSmithKline’s venture capital arm, SR One, and Kleiner Perkins Caufield & Byers. Existing investors like Biogen Idec and Google Ventures also participated, iPierian said. Since its inception i... |
| 04.09.2013 | iPierian Raises $30M; Funds True North Therapeutics | iPierian, Inc., a South San Francisco, California-based biotechnology company developing novel therapies for neurodegenerative disease, raised $30m in financing. The round was co-led by SR One, Kleiner Perkins Caufield & Byers and MPM C... |
| 26.04.2013 | Google Ventures is betting its money on these 8 healthcare and life sci companies | DNAnexus The bioinformatics company that provides DNA data management and analysis for sequencing centers and researchers was founded and is led by Andreas Sundquist. The Mountainview, California-based company provides data management suppo... |
| 07.10.2010 | Athersys CEO elected leader of regenerative medicine industry council | Athersys Inc. (NSDQ:ATHX) CEO Gil Van Bokkelen was elected chairman of the The Alliance for Regenerative Medicine. ARM says its mission is to to educate key policy makers about the potential of regenerative medicine and to advocate for favo... |
| 08.09.2010 | iPierian holds Second Closing of Series B Financing | iPierian, Inc., a South San Francisco, CA-based biopharmaceutical company using patient-derived induced pluripotent stem cells (iPSCs) for drug discovery, held the second closing of its Series B equity financing, bringing the total amount r... |
| 08.07.2010 | iPierian Closes $22M Series B Financing | iPierian, Inc., a South San Francisco, CA-based biopharmaceutical company using patient-derived induced pluripotent stem cells (iPSCs) for drug discovery, has closed a $22m Series B equity financing. The round, which brings the total amount... |
| - | Health IT deals help push software deals to 12-year high but life science struggles | Investments in electronic health records, tools to help hospitals absorb physician practices and a group working with hospital systems to help them set up their own insurance plans. Those three health IT companies helped drive venture capit... |
| - | Neuro drug developer iPierian nets $30M, spins off new company for rare disease R&D program | Rather than leveraging stem cells for therapeutic use, iPierian Inc. has been using them to create disease models with which is can screen and develop new drugs. Now, with $30 million it’s just collected from investors, iPierian Inc. plans ... |
Show more